Abstract:Objective To analyze the characteristics of dynamic blood glucose in hypoglycemia patients with different causes and explore the application value of dynamic glucose monitoring system (DGMS) in the diagnosis and differential diagnosis of hypoglycemia.Methods We used DGMS to monitor the blood glucose levels of 20 hypoglycemia patients for 3-6 days,including 6 cases of insulinoma,7 cases of reactive hypoglycemia,2 cases of autoimmune hypoglycemia,3 cases of islet cell hyperplasia,1 case of drug-induced hypoglycemia,1 case of congenital hyperinsulinism.The blood glucose profiles of hypoglycemia patients with different causes were compared.Results The average monitoring duration was (88.9 ± 10.8) hours.38-936 points of hypoglycemia were detected in these patients with hypoglycemia.The average blood glucose of patients of each cause,in the order from low to high,were:congenital hyperinsulinism [(2.97 ± 0.59) mmol/L],islet cell hyperplasia [(4.83 ± 1.32) mmol/L],insulinoma [(4.87 ± 1.37) mmol/L],drug-induced hypoglycemia [(5.98 ±0.8) mmol/L],reactive hypoglycemia [(6.38 ± 1.99) mmol/L],and autoimmune hypoglycemia [(7.63 ± 2.67) mmol/L].The constituent ratio of hypoglycemia from low to high were:autoimmune hypoglycemia and drug-induced hypoglycemia (0％),reactive hypoglycemia [0.5％ (0.0％,1.6％),insulinoma [9.0％ (5.2％,16.3％),islet cell hyperplasia [9.5％ (1.1％,14.2％),congenital hyperinsulinism (58.5％).In terms of the blood glucose profiles in day and night,the night blood glucose levels were lower than those in daytime in insulinoma [(5.16 ± 1.37) mmol/L vs.(4.44 ± 1.24) mmol/L],reactive hypoglycemia [(6.93 ±2.19) mmol/L vs.(5.57 ±1.25) mmol/L],autoimmune hypoglycemia [(8.08 ± 2.79) mmol/L vs.(6.95 ± 2.31) mmol/L],islet cell hyperplasia [(5.23 ± 1.31) mmol/L vs.(4.11 ± 1.00) mmol/L] and congenital hyperinsulinism [(3.06 ±0.57) mmol/L vs.(2.83 ±0.59) mmol/L] (all P ＜ 0.05);while the daytime blood glucose level was lower than that at night in drug-induced hypoglycemia [(5.90 ±0.81) mmol/L vs.(6.11 ±0.77) mmol/L,P ＜0.05].62.2％ and 78.9％ of the hypoglycemia episodes happened at night in patients with insulinoma and islet cell hyperplasia,and 43.2％ at night in patients with congenital hyperinsulinism.The highest standard deviation of blood glucose (2.67 mmol/L),largest amplitude of glycemic excursions (9.2 mmol/L) and coefficient of variation (35％) were found in patients with autoimmune hypoglycemia.The largest range of blood glucose (20.4 mmol/L) was found in patients with reactive hypoglycemia.The day-night differences in coefficient of variation (31.6％ vs.22.4％) and range of blood glucose (20.4 mmol/L vs.6.8 mmol/L) were most prominent in patients with reactive hypoglycemia.Conclusion The dynamic monitoring of blood glucose and the analysis of the parameters such as average blood glucose,blood glucose profiles and variability of blood glucose may be helpful for the diagnosis of hypoglycemia and differential diagnosis of causes of hypoglycemia.

Evaluation of Premixed Insulin with Dynamic Glucose Monitoring Methods

Pharmacokinetics and Pharmacodynamics of 40/60 Premixed Recombinant Human Insulin Injection Preparations

Application of Dynamic Glucose Monitoring in the Diagnosis and Differential Diagnosis of Hypoglycemia

Comparison of the effects and the security among three-injection,two-injection of premixed insulin 30R and other method used in insulin of type 2 diabetic patients

Clinical Comparison of Basal Insulin and Premixed Insulin in the Treatment of Type 2 Diabetes Mellitus

Comparison of the Therapeutic Efficacy Between Human Insulin 30R Combined with Acarbose and Insulin Aspart 30 on the Postprandial Blood Glucose in Patients with Type 2 Diabetes

Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems.

Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China.

Observation on Efficacy and Evaluation on Safety of Aspart Insulin 30 Combined with Metformin in Treatment of Type 2 Diabetes Which was Poor-Controlled by Basal Insulin Combined with Oral Hypoglycemic Drugs

In Combination with Insulin Detemir,Insulin Aspart Efficacy Evaluation of Intensive Treatment of Type 2 Diabetes

Clinical Observation on Starting Insulin after Failure of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus

[Post-Hoc Analyses of Type 2 Diabetes Patients Switch from Premixed Insulin Regimen to Basal Insulin Plus Oral Hypoglycemic Agents Regimen].

Comparison of the Effect Between Insulin Lispro 75/25 and Humulin 70/30 on the Postprandial Blood Glucose Excursion in Patients with Diabetes

A 2-Way Cross-Over, Open-Labeled Trial to Compare Efficacy and Safety of Insulin Aspart and Novolin R Delivered with CSII in 21 Chinese Diabetic Patients

Efficacy and Safety of Insulin Detemir Plus Insulin Aspart Versus NPH Insulin Plus Human Soluble Insulin with or Without Metformin in Chinese Type 2 Diabetes

Comparison of efficacy and safety of insulin glulisine and insulin aspart in treatment of islet beta cell dysfunction in type 2 diabetes patients

Dosage of Insulin Treatment on Newly Diagnosed Type 2 Diabetics

Biphasic insulin aspart-30 reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once-daily insulin regimens using continuous glucose monitoring

Therapeutic Comparison on Insulia Aspart 30 and Novolin 30R in the Treatment of Type Two Diabetes Mellitus after Failure to Oral Hypoglycemic Agents

Dynamic evaluation of blood glucose fluctuations in type 2 diabetic and normal subjects

Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes